Patheon Completes Intermediate Scale Processing Facility at its Cincinnati Plant

    TORONTO, Oct. 9 /CNW/ - Patheon (TSX:PTI), a global provider of drug
development and manufacturing services to the international pharmaceutical
industry is pleased to announce the expansion of services utilizing a new
Intermediate Scale Processing Suite (ISPS), located at the Cincinnati, Ohio
facility. The ISPS provides increased manufacturing capacity that will bridge
the gap between Patheon's development and commercial scale facilities.
    The new ISPS equipment includes an intermediate scale Diosna-P300 high
shear granulator coupled with Niro-MP4 fluid bed dryer with solvent and high
potency compound handling capabilities. This added suite will allow the
production of batch sizes ranging from 35-115 kg. The ISPS will allow Patheon
to meet the Development, Clinical, Registration, Scale-up, Validation and
Commercial requirements for customers. The expansion of services will also
help to develop robust processes as projects move from development to
commercial using statistical design of experiments, to support the FDA's
Quality by Design (QBD) initiative. The ISPS provides greater flexibility in
scheduling experiments on a larger scale and uses less active pharmaceutical
ingredients (API) compared to commercial scale.
    Terry Novak, President, North America and Chief Marketing Officer, at
Patheon stated "The ISPS provides us with another valuable service to address
the unique needs of our customers. By adding this equipment we will be able to
reduce time and resources it takes to moving a new product though


    Patheon Inc. (TSX:PTI; is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
    Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API. Patheon's integrated network strives to
ensure that customer products can be launched with confidence globally.

    Caution Concerning Forward-Looking Statements

    This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at or on SEDAR at

    %SEDAR: 00001700E

For further information:

For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (905) 812-2112, Email:; Mr. Eric Evans,
Chief Financial Officer, Tel: (905) 812-6660, Email:;
Ms. Jean Treadwell, Investor Relations, Tel: (905) 816-8344, Email:

Organization Profile

Patheon Inc

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890